Every material Form 8-K PROKIDNEY CORP. has filed with the SEC since May 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.
Cash and marketable securities were $141.9 million as of September 30, 2026.
The updated investor presentation says current cash is expected to support operating plans into mid-2027.
The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
The filing does not include revenue, net income or loss, or earnings per share.
ProKidney entered into an Open Market Sale Agreement with Jefferies LLC on October 29, 2026, allowing it to sell up to $200 million of Class A common stock from time to time through the agent. Sales depend on the effectiveness of a Form S-3 shelf registration filed the same day, and the company has no obligation to sell any shares, so future share issuance could dilute existing shareholders if sales occur.
Agreement with Jefferies LLC dated October 29, 2026, covers up to $200,000,000 in Class A common stock
Jefferies compensation is up to 3.0% of gross offering proceeds, plus reimbursement of specified expenses
Sales require the Form S-3 shelf registration filed October 29, 2026 to become effective; the company has no obligation to sell shares
ProKidney reported a second-quarter 2026 net loss before noncontrolling interest of $46.4 million, up from $37.0 million a year earlier, as research and development expenses rose to $36.1 million from $25.9 million, mainly on the Phase 3 PROACT 1 study. Cash, cash equivalents and marketable securities fell to $181.6 million from $224.9 million at March 31, 2026, and the company said this supports operations into mid-2027. Shareholders face a larger loss per share and a lower cash balance, though the company completed enrollment for the accelerated approval analysis.
Net loss per Class A share was $0.15 for the quarter, compared with $0.13 a year earlier
Revenue was $150 thousand, compared with $221 thousand in the second quarter of 2025
Cash, cash equivalents and marketable securities totaled $181.6 million at June 30, 2026, down from $224.9 million at March 31, 2026
Kenneth Locke was appointed Chief Technical Officer in June 2026; topline results from the PROACT 1 accelerated approval analysis are anticipated in Q2 2027
ProKidney reported first-quarter 2026 results, with its net loss before noncontrolling interest widening to $42.6 million from $38.0 million a year earlier and revenue of $226 thousand against $230 thousand. The company also updated its Phase 3 PROACT 1 statistical powering assumption for the eGFR slope analysis to 80%, and said its cash supports operations into mid-2027, which matters to shareholders because the company's cash balance is declining while it funds the pivotal study.
Q1 2026 net loss before noncontrolling interest was $42.6 million, versus $38.0 million in Q1 2025; net loss per Class A share was $(0.14), versus $(0.13)
R&D expenses rose to $33.8 million from $27.3 million, driven mainly by PROACT 1 clinical study and manufacturing costs; G&A fell to $11.3 million from $14.4 million
Cash, cash equivalents and marketable securities totaled $224.9 million at March 31, 2026, down from $270.0 million at December 31, 2025; the company expects this to fund operations into mid-2027
PROACT 1 enrollment for the accelerated approval analysis is on track for mid-2026, with pivotal topline results expected in Q2 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PROKIDNEY CORP. filing is on SEC EDGAR ↗. 8-K briefs of other companies →